Part of Abbott’s Healon family of ophthalmic viscosurgical devices, the device intended for use as a surgical aid in cataract extraction and intraocular lens implantation.
It is a clear, viscous, protective gel formula that is intended to be injected into a patient’s eye to protect and coat the eye during surgery.
“Healon OVDs offer the surgeon the ultimate in control, clarity and ease-of-use during every step of the cataract procedure,” said Jim Mazzo, senior vice president, Abbott Medical Optics, in the release. “The U.S. approval of Healon EndoCoat OVD adds to a reliable portfolio of OVDs that has been known and trusted for more than 25 years and proven safe worldwide.”
Abbott is headquartered in Chicago.
Related Articles on FDA Clearances:
ProPep Surgical Receives FDA Clearance for Nerve Monitoring System
Ultrasonix Medical Receives FDA Approval for Needle Guidance Technology
Synergetics Receives FDA Clearance for Versavit Vitrectomy System
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.